Phamacology Core

药理学核心

• 批准号: 8117618
• 负责人: Noelle Sevilir Williams
• 金额: $ 19.11万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8117618
• 关键词: Address; Animal Model; Behavior; Biological Assay; Cancer Center; Cancer Patient; Cell Culture Techniques; Cell Line; Cessation of life; Characteristics; Chemistry; Clinical; Commit; Communities; Comprehensive Cancer Center; Core Facility; Development; Disease; Dose; Drug Kinetics; Ensure; Equipment; Evaluation; Experimental Designs; Future; Goals; In Vitro; Individual; Ireland; Malignant Neoplasms; Measurement; Medical center; Metabolic; Metabolism; Modeling; Monitor; Mycoplasma; NCI-Designated Cancer Center; Patients; Pharmacology; Plasma Proteins; Positioning Attribute; Process; Program Research Project Grants; Property; Protein Binding; Research; Research Personnel; Resource Sharing; Resources; Rodent Model; Screening procedure; Services; Solubility; Standardization; Structure; Testing; Time; Toxic effect; Universities; University Hospitals; Work; Xenograft procedure; absorption; animal colony; animal resource; anticancer research; base; chemical synthesis; design; experience; fighting; in vivo; member; mouse development; novel; novel therapeutics; operation; pathogen; programs; research study; small molecule; success; tumor

The Pharmacology Core facility will be responsible for the design, execution, and analysis of experiments that address metabolic stability, general in i//Vo toxicity, pharmacokinetics, and in vivo efficacy of anti-cancer compounds generated by this Program Project Grant (PPG). In addition, they will maintain the cell lines, animal resources, and equipment that support these functions. It is anticipated that all four projects of this PPG may potentially have need for the services provided by this Core facility. In addition, the Core will serve as a resourcefor members of the UT Southwestern Medical Center (UTSWMC) Comprehensive Cancer Center needing assistance with pharmacological assays. Since there are no other facilities here that can provide in-depth analysis of the behavior of novel small molecules in an in vivo setting, the creation of such a shared resource has the potential to impact the future development of translational cancer research at UTSWMC. The services provided by the Core facility will include: in vitro screening of compounds against a broad tumor panel; characterization of the metabolic stability of individual compounds in vitro and identification of metabolites as necessary; assessment of the solubility, plasma protein binding, and absorption characteristics of compounds in vitro; determination of the maximum in vivo tolerated dose and a preliminary assessment of toxicity; assessment of the distribution of compounds in small rodent models (pharmacokinetics); and development of mouse xenograft or other appropriate models for assessment of compound efficacy in vivo. The Pharmacology Core facility will work closely with PPG chemists to refine the structure of individual compounds so that characteristics that favor optimal efficacy in vivo will be maximized. There is an urgent need for new therapeutics to fight cancer, which in 2005 was responsible for over 500,000 deaths. The overall goal of this Program Project grant (PPG) is to discover and characterize synthetic, small molecule compounds that may be effective in the treatment of this disease. The Pharmacology Core facility will perform in vitro and in vivo measurements of compound concentration, toxicity, and efficacy in animal models. The overall goal of the Core is to guide chemical synthesis efforts of PPG projects in such a way that novel molecules with the best chance of clinical success in cancer patients are generated.

药理学核心设施将负责实验的设计、执行和分析 解决代谢稳定性、i//Vo 毒性、药代动力学和体内抗癌功效的一般问题 由该计划项目拨款（PPG）产生的化合物。此外，他们还将维护细胞系， 动物资源以及支持这些功能的设备。预计本次四个项目全部 PPG 可能需要该核心设施提供的服务。此外，该核心将服务于 作为 UT 西南医学中心 (UTSWMC) 综合癌症成员的资源 中心需要药理学测定方面的帮助。由于这里没有其他设施可以 深入分析新型小分子在体内的行为，创建这样的 共享资源有可能影响转化癌症研究的未来发展 UTSWMC。核心设施提供的服务将包括： 体外筛选化合物 广泛的肿瘤组；单个化合物的体外代谢稳定性表征 必要时鉴定代谢物；溶解度、血浆蛋白结合的评估，以及 化合物的体外吸收特性；体内最大耐受剂量的测定和 毒性初步评估；小型啮齿动物模型中化合物分布的评估 （药代动力学）；以及开发小鼠异种移植物或其他适当的模型来评估 体内复合功效。药理学核心设施将与 PPG 化学家密切合作，完善 单个化合物的结构，以便最大限度地发挥有利于体内最佳功效的特性。 迫切需要新的疗法来对抗癌症，2005 年癌症导致超过 500,000 人死亡 死亡人数。该计划项目拨款 (PPG) 的总体目标是发现和表征合成的、小型的 可能有效治疗这种疾病的分子化合物。药理学核心设施 将在动物体内进行化合物浓度、毒性和功效的体外和体内测量 模型。核心的总体目标是以这种方式指导PPG项目的化学合成工作 产生在癌症患者中最有可能获得临床成功的新分子。